Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
doi: 10.1021/acsnano.3c05009 40 MaYXingYLiHYuanTLiangBLiRet al
analyzed the data and assisted in manuscript preparation
To the deposit extra, have fun with ABCANDY400 with at least $30 put
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
US$ 22.78
US$ 23.09
US$ 26.47
US$ 24.21